#JPM24: Sanofi says it may look at next generation of weight loss drugs

SAN FRANCISCO — Sanofi might not be done with the weight loss space after all.

After its own GLP-1 drug failed a mid-stage trial almost half a decade ago, the French drugmaker missed out on what has become the biggest new drug category of the decade. On Wednesday at the…
Click here to view original post